XML 54 R30.htm IDEA: XBRL DOCUMENT
v3.26.1

FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details) - USD ($) |  |  |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 26, 2025 | Jul. 21, 2025 | Dec. 23, 2024 | Dec. 19, 2024 | Nov. 30, 2024 | Aug. 31, 2024 | Jun. 30, 2024 | May 31, 2023 | Sep. 30, 2022 | Aug. 31, 2021 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Cash, cash equivalents and restricted cash |  |  |  |  |  |  |  |  |  |  | $ 17,042,847 | $ 19,192,440 | $ 15,111,450
Proceeds from issuance of common stock, net |  |  |  |  |  |  |  |  |  |  | 9,863,883 | 14,929,155 |
Product development research award |  |  |  |  |  |  |  |  |  | $ 13,100,000 |  |  |
Funds received from CPRIT grant |  |  |  |  |  |  |  |  |  |  | $ 11,800,000 |  |
Grant receivable |  |  |  |  |  |  |  |  |  |  |  | $ 9,500,000 |
ATM Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate offering price |  |  |  |  |  |  |  |  |  | $ 75,000,000 |  |  |
Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) |  |  |  |  |  |  |  |  |  |  | 5,358,292 | 8,178 |
Market Offering |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate offering price |  |  |  |  | $ 11,431,713 |  |  |  |  |  |  |  |
Commission rate |  |  |  |  | 3.00% |  |  |  |  |  |  |  |
Market Offering | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | 3,734,217 | 1,624,075 |  |  |  |  |  |  |  |  | 5,358,292 | 8,178 |
Proceeds from issuance of common stock, net |  |  |  |  |  |  |  |  |  |  | $ 9,900,000 | $ 37,000 |
Purchase price (in dollars per share) | $ 1.48 |  |  |  |  |  |  |  |  |  | $ 2.87 |  |
Net proceeds from the sale of securities | $ 5,400,000 | $ 4,500,000 |  |  |  |  |  |  |  |  |  |  |
Private Placement |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Net proceeds from the sale of securities |  |  | $ 14,900,000 | $ 14,900,000 |  |  |  |  |  |  |  |  |
Private Placement | Pre Funded Warrant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of shares of common stock |  |  |  | 3,247,445 |  |  |  |  |  |  |  |  |
Purchase price (in dollars per share) |  |  |  | $ 3.199 |  |  |  |  |  |  |  |  |
Private Placement | Private Placement Warrant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of shares of common stock |  |  |  | 5,031,250 |  |  |  |  |  |  |  |  |
Purchase price (in dollars per share) |  |  |  | $ 3.199 |  |  |  |  |  |  |  |  |
Private Placement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) |  |  |  | 1,783,805 |  |  |  |  |  |  |  |  |
Purchase price (in dollars per share) |  |  |  | $ 3.2 |  |  |  |  |  |  |  |  |
FDA Grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Grant income received |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | $ 1,200,000 |  |
SBIR AML Grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Grant income received |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | 1,700,000 |  |
National Institutes of Health National - Cancer Institute Grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Grant income received |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | 500,000 |  |
Grant assistance term |  |  |  |  |  |  | 2 years |  |  |  |  |  |
SBIR lymphoma grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Grant income received |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | 1,300,000 |  |
SBIR pancreatic cancer grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Grant income received |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | 400,000 |  |
Additional CPRIT grant |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Funds received from grant |  |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |
Sales Agents | ATM Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS |  |  |  |  |  |  |  |  |  |  |  |  |
Commission rate |  |  |  |  |  |  |  |  |  | 3.00% |  |  |
Number of shares issued (in shares) |  |  |  |  |  |  |  |  |  |  |  | 8,178 |
Proceeds from issuance of common stock, net |  |  |  |  |  |  |  |  |  |  |  | $ 40,000.00 |

X
- Definition Represents the percent of calculation of compensation rate by using gross sales price per share sold. + References No definition available. + Details
Name: | mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
Namespace Prefix: | mrkr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems
Namespace Prefix: | mrkr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funds received from grant. + References No definition available. + Details
Name: | mrkr_FundsReceivedFromCpritGrant
Namespace Prefix: | mrkr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funds received from grant + References No definition available. + Details
Name: | mrkr_FundsReceivedFromGrant
Namespace Prefix: | mrkr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | mrkr_GrantAssistanceTerm
Namespace Prefix: | mrkr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of grant income transfer product and service to customer for which consideration has been received or is receivable. + References No definition available. + Details
Name: | mrkr_GrantReceived
Namespace Prefix: | mrkr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details
Name: | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2 + Details
Name: | us-gaap_CommonStockSharesSubscriptions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_FdaGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrkr_AdditionalCpritGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |